

Wyeth Pharmaceuticals

New Lane
Havant
Hampshire, PO9 2NG
Tel: +44 (0)2392 483611
Fax: +44 (0)2392 478523



NEWS RELEASE

New investment at Wyeth Pharmaceuticals' Havant site

Havant, Hampshire, 25 May 2007 - Wyeth is making new investments at its site in New Lane, Havant in response to growing worldwide demand for the Company's vaccine Prevenar*▼, a vaccine which helps protect babies and young children from life-threatening diseases, such as pneumococcal meningitis, and other infections.

The new investment – which totals £3.25 million - has seen the installation of a second packaging line for Prevenar. This will enable the Havant site to boost the number of vaccines packaged and distributed from Havant to a projected 22 million this year from just 10 million in 2005.

"This new investment is a very exciting development for our manufacturing and distribution base here at Havant and is a clear indication of the Company's commitment to the site," says Plant Director, Dr Jim Neville.

"At Havant, we have a key role within Wyeth's global operations as a highly specialised facility, managing the packaging and distribution of some of the Company's most advanced medicines and vaccines," adds Dr Neville. "Packaging and distribution of these products is a complex and demanding process, requiring their temperature to be maintained at between 2 and 8° C throughout all stages of the packaging and distribution process."

Dr Neville goes on to say: "This type of development really puts Wyeth's Havant facility on the map of global distribution. It's very refreshing to see this kind of investment locally here in the UK, and we look forward to seeing the continued expansion of our role."

Operations Director, Val Latham, says that the new line is operated by two teams of ten staff each working an eight-hour shift. "Having a second line relieves the pressures on an already busy team," she adds. "The new line also means we'll have the capacity to handle new vaccines which we are currently researching."



John Wyeth & Brother Limited
Registered in England No. 135937
Registered Office: Huntercombe Lane South
Taplow, Maidenhead, Berkshire, SL6 0PH

/2...

Operator, Sharon Taylor, is one of the first members of the team to work on the new line: "At first, it took a bit of getting used to because of changes in equipment design and technology but we've all risen to the challenge. Team spirit is high! It's great to know that the product we produce is helping to save children's lives."

Since September last year, Prevenar has been part of the UK's routine childhood immunisation programme. In addition, Wyeth's Havant facility also exports Prevenar to European, Latin American, and Asia Pacific markets, for immunisation programmes in countries such as France, Germany, Spain, Holland and Australia. The Havant site is also responsible for packaging and distributing Meningitec*, another Wyeth vaccine used in the UK routine childhood immunisation programme.

Over 500 people are employed by Wyeth Pharmaceuticals at the Havant site. The company has been part of the Havant business community since 1957 and this summer the site will celebrate its 50th birthday.

- ends -

**For further information, please contact:
David Gibbons on 01628 604 377 or email at gibbonsd@wyeth.com**

NOTES TO EDITORS

Wyeth is one of the world's leading research-driven pharmaceutical companies with a major focus on developing innovative new medicines to improve health and well being. Each year, Wyeth invests over \$2 billion in new product development and research.

Wyeth ranks amongst the UK's top pharmaceutical companies with a portfolio of leading products across a wide range of treatment areas.

Wyeth's Prevenar vaccine against pneumococcal disease helps prevent infections such as meningitis, blood poisoning, and pneumonia in babies and young children. It also helps protect against some of the ear and chest infections children commonly suffer¹. All babies born in the UK are now offered three doses of the vaccine at 2, 4 and 13 months respectively. In addition, there has been a catch-up campaign to help ensure that all children under the age of 2 years are offered protection as well².

Wyeth's vaccine Meningitec, against meningitis C, was the 1st meningococcal group C conjugate vaccine to be introduced. Its availability in 1999, enabled the Department of Health to begin its life-saving immunisation programme against this form of meningitis³.

References

1. Summary of Product Characteristics Prevenar PFS, electronic Medicines Compendium.<http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp&documentid=17771> ; accessed May 21, 2007.
2. Chief Medical Officer Letter, July 2006:
<http://www.dh.gov.uk/assetRoot/04/13/71/75/04137175.pdf>
3. Chief Medical Officer Letter, October 1999
http://www.dh.gov.uk/prod_consum_dh/idcplg?ldcService=GET_FILE&dID=2622&Rendition=Web

* Trade Mark

ZPRE900

Date of preparation: May 2007